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Demographics and Epidemiological Aspects  
of Arterial Hypertension in the Very Old
The prevalence of arterial hypertension is constantly rising, 
mainly as the result of the aging of the population, in par-
ticular, the increase in the population over 80 years old, 
which has expanded exponentially over the past 40 years.1 
Currently, the life expectancy for those 80 years and over liv-
ing in the OECD (Organisation of Economic Cooperation and 
Development) group of countries is ≈9 years compared with 
about 6 years in the 1970s, representing an increase of 50%.2 
In the European Union, there were 27.3 million people aged 
80 years and older in 2016 (5.4% of the total population) ver-
sus 20 million in 2006 (4.6% of the total population.3 In the 
United States, the percentage of people of 80 years and older 
is projected to be 7.4% in 2050,4 which is exactly double the 
percentage observed in 2010. These demographic changes 
explain why, despite the fact that the incidence of hyperten-
sion at a given age has changed very little,5 the absolute num-
ber of individuals with hypertension is constantly growing. 
Observational data from the Framingham Study suggest that 
the lifetime risk of developing hypertension is >90% for an in-
dividual aged 55 to 65 years.6 Thus, the continuously increas-
ing number of older individuals ultimately leads to a growing 
population with high blood pressure (BP). In addition, the 
aforementioned demographic changes concomitantly lead to 
a greater number of older people in need of both home and 
institutionalized care because of cognitive and functional de-
cline, frailty, multimorbidity, polypharmacy, as well as partial 
or complete loss of autonomy.7,8
Indeed, the number of very old individuals exhibiting 
frailty (ie, a state of vulnerability to poor resolution of home-
ostasis after a stressor event and a consequence of cumula-
tive decline in many physiological systems during a lifetime),9 
loss of autonomy, and limited life expectancy have dramati-
cally increased worldwide. In European countries, the num-
ber of people living in nursing homes (NHs) has increased 
sharply over the past decade10 such that, in 2013, there were 
3.7 million long-term care beds in nursing and residential care 
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facilities in the European Union, with the number of beds 
constantly increasing. For example, between 2011 and 2014, 
the number of NH beds in France increased from ≈611 000 to 
634 500 and from 220 000 to 234 000 beds in Italy. In addition 
to those living in NHs, and partly because of a saturation of 
the capacity of institutionalized care, many community-dwell-
ing older people have advanced frailty with limited autonomy; 
these individuals also require assistance for basic daily activ-
ities. For instance, data from the French National Institute of 
Statistics and Economic Studies11 show that among individu-
als aged 80 and over, 650 000 live in the community and re-
ceive Autonomy Personalized Allocation. in addition to the 
600 000 who live in NHs. Thus, in France one-third of the total 
80+ population (1.25 out of 3.80 million people) present a sig-
nificant loss of autonomy with consequently increased need 
for permanent assistance in activities of the daily living.
Of greater issue is the fact that loss of autonomy, living 
in an NH, or significant cognitive decline are constant exclu-
sion criteria (or lead to refusal) in clinical trials studying the 
clinical interest of medications for chronic diseases.12 Data 
from France and Italy show that >80% of NH residents have 
a diagnosis of arterial hypertension, over 80% of who receive 
antihypertensive medication.13 However, very old frail people 
are not included in randomized controlled trials (RCTs) pri-
marily because they have limited autonomy, multiple comor-
bid conditions (including cognitive impairment), thus leading 
to refusals and difficulties in analyses because of competitive 
mortality. Placebo-controlled studies are moreover particu-
larly difficult, given that a change in existing treatment may 
not be ethically acceptable. Furthermore, running RCTs in 
NHs creates a higher level of difficulty related to14
 • Multilevel decision-making (involvement of family 
members and others).
 • Medical support not tailored to clinical research stan-
dards (small and poorly trained staff that is sporadically 
overseen by physicians).
 • Increased administrative burden (a high degree of reg-
ulation and concern about regulatory sanctions and an 
abundance of required time-consuming documentation).
Given the lack of trials that have included older patients with 
the aforementioned severe frailty and decreased autonomy 
profile, the benefit/risk ratio of antihypertensive treatment 
(as well as treatment of several other chronic diseases that 
affect older people), is thus primarily based on evidence ob-
tained in individuals who are more robust, mildly/moderately 
frail at most, present fewer comorbidities, and receive less 
medication.
Simply stated, very old frail people who reside in NHs 
are usually prescribed medications, the benefits of which 
are based on research in younger and healthier populations. 
This is of particular concern for the treatment of arterial 
hypertension, one of the most common conditions in older 
adults. There is evidence that for general older populations 
with chronic conditions and cardiovascular drug treatment 
(Medicare beneficiaries), survival does not necessarily dif-
fer from that observed in RCTs.15 However, with an older 
patient, it often happens that medication, once appropriately 
initiated, is not routinely reevaluated in conditions of a de-
teriorating cognitive and functional state and a decreasing 
life expectancy. Therefore, in older patients presenting ad-
vanced or terminal disease, dementia, severe frailty or full 
dependence, and those receiving high-risk drugs or combi-
nations thereof, the meticulous tailoring of pharmacother-
apy—even including deprescribing (see below)—should be 
considered.16,17
Changes in BP During the Aging Process: the 
Role of Arterial Stiffness and Comorbidities
Increase in Systolic BP and Decrease in Diastolic BP 
With Age
Arterial stiffness is the major cause of elevated systolic 
BP (SBP) and pulse pressure (PP, SBP minus diastolic BP 
[DBP]) as well as lower DBP in older adults. Moreover, 
these BP age-related alterations are powerful determinants 
of major cardiovascular disease (CVD) events and all-cause 
mortality.18–20
Until the age of 50 to 60 years, both SBP and DBP in-
crease with age. Over the age of 60 years, in the majority of 
cases, SBP increases with age, whereas DBP concomitantly 
remains stable or even decreases spontaneously. The most 
common cause for the disruption of the correlation between 
SBP and DBP—leading to an excessive increase in PP—is 
the progressive stiffening of the arterial wall.18,19 Indeed, arte-
rial stiffness arises as a consequence of several structural and 
functional changes of the large arteries. Wall hypertrophy, cal-
cifications, and atheromatous lesions, as well as changes in the 
extracellular matrix (such as an increase in collagen and fibro-
nectin, fragmentation and disorganization of the elastin net-
work, nonenzymatic crosslinks and cell-matrix interactions), 
are the main structural determinants of the decrease in elastic 
properties and the development of large artery stiffness.20 In 
addition, functional changes, such as impaired vascular endo-
thelial function and modification of smooth muscle cell reac-
tivity, contribute to the stiffening of the arterial wall.
It should be emphasized that SBP is dependent on both 
left ventricular performance and on stiffness of the aorta and 
other large arteries.18,21 As a result, peak systolic pressure will 
be greater if the arterial wall is more rigid. However, after 
closure of the aortic valves, arterial pressure gradually falls 
as blood is drained to the peripheral vascular networks. The 
Nonstandard Abbreviations and Acronyms
ADL activities of daily living
BP blood pressure
CGA comprehensive geriatric assessment
CSHA Canadian Study of Health and Ageing
DBP diastolic blood pressure
HYVET Hypertension in the Very Elderly Trial
IADL instrumental activities of daily living
NH nursing
 home
PP pulse pressure
SBP systolic blood pressure
SPRINT Systolic Blood Pressure Intervention Trial
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minimum diastolic pressure is determined by the duration of 
the diastolic interval and the rate at which the pressure falls. 
The rate of fall in pressure is influenced by peripheral resist-
ance and by the visco-elastic properties of the arterial wall. At 
a given vascular resistance, the fall in diastolic pressure will 
be greater if large artery stiffness is augmented. The visco-
elastic properties of arterial walls are also a determinant of the 
speed of propagation of the arterial pressure wave (pulse wave 
velocity) and of the timing of wave reflections. Thus, stiffen-
ing of the arteries increases pulse wave velocity and may be 
responsible for an earlier return of the reflected waves, which 
is superimposed to the incident pressure wave, thereby further 
contributing to the increase in SBP and PP.21
Impaired BP Homeostasis and Increased BP 
Variability
Postural as well as other BP variations increases in older 
adults. Orthostatic hypotension is the most common expres-
sion of these variations and is considered as a risk factor for 
cardiovascular and noncardiovascular morbidity and mor-
tality.22 Orthostatic hypotension is related to several chronic 
diseases: hypertension, chronic autonomic failure in the con-
text of Parkinson disease and other neurological diseases, 
polyneuropathy mainly in the context of diabetes mellitus. 
Nonneurogenic orthostatic hypotension is largely attributable 
to several conditions often observed in older adults, namely 
dehydration and polypharmacy (especially in case of vasodila-
tors, diuretics, and psychotropic medications).23
In addition, the presence of large artery stiffness leads to 
impaired activation of the baroreflex24 and inappropriate BP/
heart rate response to postural changes.25 Several studies have 
shown that stiffer large arteries contribute to greater BP var-
iability during orthostatic reactions inducing both orthostatic 
hypotension26 and orthostatic hypertension.27
Arterial stiffness is also implicated in the increased varia-
bility in BP observed in several other conditions, such as exer-
cise,28 postprandial BP variations (both increase and decrease 
in BP are exaggerated in individuals with pronounced arterial 
stiffness),29 and between-visit BP variability.25 These observa-
tions indicate that large artery stiffness contributes to inappro-
priate homeostatic mechanisms responsible for maintaining 
both BP and tissue perfusion stability during various physio-
logical conditions.
Modifications in orthostatic BP have been shown to af-
fect the prognosis of older people30,31 by increasing the risk 
of syncope and falls, leading to hospitalization and functional 
impairment,32,33 in addition to increasing CVD and all-cause 
mortality.31,34 Somewhat paradoxically, orthostatic reactions 
may be alleviated with better hypertension control.35
Although the complications of orthostatic hypotension are 
well known, a growing number of clinical studies indicate that 
an increase in BP in the upright position (orthostatic hyper-
tension) is also an independent risk factor of cerebrovascular 
disease36–38 and other target organ damage.37–39 A prospective 
study showed that orthostatic hypertension was associated 
with a higher risk of developing hypertension later in life.40
We have moreover recently reported that orthostatic hy-
pertension in very old subjects living in NHs was related to an 
increased risk of CVD morbidity/mortality in a manner simi-
lar to that observed with orthostatic hypotension.30
Impact of High BP Values in Older Subjects
Respective Roles of SBP, DBP, and PP
SBP and PP are better indicators of CVD risk in older sub-
jects, whereas in younger subjects, DBP is a better reflection 
of CVD risk.41,42 The age-dependent changes in the prognostic 
value of BP levels are related to the age-related modifications 
of SBP and DBP, as presented in the previous section. DBP 
in young patients is primarily dependent on peripheral resist-
ance, and therefore low DBP is a reflection of low peripheral 
resistance. Moreover, in young subjects with hyperkinetic cir-
culation, DBP is less variable than SBP, thus better-reflecting 
CVD risk. In older subjects, a low DBP mainly reflects high 
arterial stiffness, which is a major manifestation of arterial ag-
ing rather than low peripheral resistance (Table 1).18,19,21 In this 
instance, low DBP is associated with high SBP/PP values and 
increased CVD risk. The clinical application of these consid-
erations is that, in people older than 55 to 60 years, SBP is a 
much more important CVD risk factor than DBP.43 All of the 
recent guidelines highlight that, in older adults, SBP seems to 
be a better predictor of events than DBP.44 Moreover, PP can 
Table 1. Schematic Representation of the Various BP Profiles in Older Subjects
Age, y SBP DBP
BP Regulation 
Physiopathology Main Risks Better BP Risk Marker Management
65–80 ↑ ↑ ↑ High PR and AS CV complications, 
cognitive decline
High SBP Physical activities, a
ssess TOD and global CVR, 
medical tt (SBP <140)
65–80 ↑ ↔ ↓ High AS CV complications, c
ognitive decline
High SBP, PP, l
ow DBP
Physical activities, a
ssess TOD and global CVR, 
medical tt (SBP <140)
>80 ↑ ↑ ↔ ↓ High AS CV complications, 
falls
High PP, low 
DBP, OH
CGA, medical tt
(SBP <150 or SBP <140 according 
functional status)
>80 ↔ ↓ ↓ ↔ High AS and c
omorbidities
CV complications, 
falls, loss of autonomy
Normal/low SBP, low DBP; 
normal/high PP, OH
CGA, deprescribing if SBP <130 or 
OH, fight polypharmacy
AS indicates arterial stiffness; BP, blood pressure; CGA, Comprehensive Geriatric Assessment; CV, cardiovascular; CVR, cardiovascular risk; DBP, diastolic 
blood pressure; OH, orthostatic hypertension; PP, pulse pressure; PR, peripheral resistance; SBP, systolic blood pressure; TOD, target organ damage; and tt, 
treatment.
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have an additional prognostic value in individuals aged over 
65 to 70 years reflecting the fact that, in older adults, a high 
SBP carries a greater risk when associated with a low DBP.45 
Finally, for reasons developed later in this article, in very old, 
frail, multimorbid subjects, SBP also becomes less informa-
tive for the definition of CVD risk.
High BP and Cardiovascular Complications
Several large population studies have indicated that the 
higher the office BP, the higher the risk of stroke and cor-
onary heart disease, sudden death, heart failure, peripheral 
artery disease, and end-stage renal disease. Although some 
studies suggest that BP has limited predictive value for total 
mortality after the age of 70 years,46 large epidemiological 
studies have shown that the associations between BP and 
CVD events are observed in the majority of subjects aged 
over 80 years.47 However, although for the general popula-
tion the relationship with BP extends from high BP levels to 
relatively low values (110–115 mm Hg for SBP and 70–75 
mm Hg for DBP), in older populations, these lower thresh-
olds are variable depending on the age and functional sta-
tus of the studied subjects. A continuous relationship with 
events is also exhibited by out-of-office BP values, such as 
those obtained by ambulatory BP measurements and home 
BP measurements.
Metabolic risk factors are more common when BP is high 
than when BP is low.48,49 However, particularly in older sub-
jects aged over 80 years, the role of certain metabolic factors, 
notably dyslipidemia, is much less established.50 This does 
not exclude, however, that treatment of dyslipidemia may be 
beneficial, although RCTs proving or disproving the latter are 
currently lacking.51
Impact of Hypertension on Neurocognitive 
Performance
Observational studies have documented an association be-
tween elevated BP in middle age and the risk of cognitive im-
pairment. This relationship was observed for the first time in 
the Framingham study in which a high BP detected 20 years 
earlier was inversely associated with cognitive performance 
among untreated hypertensive subjects.52 Since this initial ob-
servation, most epidemiological studies have confirmed this 
relationship between hypertension and cognitive decline.53 
For example, the Honolulu-Asia Aging Study which followed 
3735 subjects for over 30 years showed that the risk of cogni-
tive decline at age 78 increased with the level of BP measured 
25 years earlier.54 In a seminal study in the field, Skoog et al55 
showed that over a follow-up period of 10 to 15 years, patients 
with hypertension developed dementia more frequently than 
normotensive subjects. On an even shorter follow-up period of 
4 years, the Epidemiology of Vascular Aging study found the 
risk of cognitive decline to be multiplied by 6 among patients 
with untreated chronic hypertension compared to a normoten-
sive group.56 However, such relationship between BP levels 
and cognitive decline in older populations was not observed in 
other clinical studies.57 Hypertension duration, testing meth-
ods, as well as differences in the tested population may ex-
plain these discrepancies. In addition, the current concept is 
that midlife BP level is more important as a risk factor for 
late-life cognitive impairment and dementia than BP levels as-
sessed in late-life.58
The relative failure of antihypertensive treatments in pre-
venting neurocognitive diseases observed in clinical trials in 
older hypertensive subjects is likely because of the relative 
short duration and late onset of these studies.53,59,60 In fact, al-
though a reduction in BP levels can be achieved with anti-
hypertensive therapy, vascular and cerebral alterations caused 
in part by long-term hypertension precede treatment and thus 
cannot be reversed by such intervention. This hypothesis may 
also explain why in several studies, markers of arterial aging 
can potentially identify subjects at higher risk of cognitive 
decline, whereas BP levels alone do not seem to have a sig-
nificant predictive value.61–63 Finally, recent epidemiological 
data from the Framingham study report a strong reduction in 
the incidence of neurocognitive syndromes between 1977 and 
2008, with one of the more plausible explanations of this ob-
servation being the improvement in BP control in the popula-
tion, especially in middle-aged hypertensive subjects.64
BP and Reverse Causality
Several studies have challenged the classical association be-
tween hypertension and CVD or all-cause mortality in the 
very old and even observed inverse associations between 
both systolic and DBP and mortality.65–68 A decline in BP 
over time in older subjects with hypertension is common and 
has even been observed in the control group of the HYVET 
(Hypertension in the Very Elderly Trial) as well as being as-
sociated with increased mortality.69,70 BP may also decrease 
in these subjects as a result of cardiovascular and neurolog-
ical comorbidities, loss of weight, dehydration, as well as 
polypharmacy. Irrespective of the underlying mechanism(s), 
whereas a decreasing BP is a marker of declining health, a 
high BP may conversely become a marker of good health in 
a phenomenon of reverse causality. In the presence of arte-
rial stiffness, declining BP may further decrease an already 
low DBP, which in turn leads to lower coronary perfusion.71 
Thus, the issues of reverse causality confound the risk strat-
ification according to BP levels. Alternative approaches for 
the estimation of CVD risk in these subjects—such as direct 
measurements of functional arterial characteristics (pulse 
wave velocity, PP amplification, endothelial function, etc)—
may indeed provide better information.13,72 The progressive 
decline in BP over time in older patients also suggests that 
the requirements for antihypertensive treatment may decrease 
over time.
Interestingly, in very old frail subjects, several recent ob-
servational studies have shown that low SBP levels (SBP <130 
mm Hg) were associated with higher morbidity and mortality 
rates in those receiving BP-lowering drugs but not in those 
with spontaneously (nondrug-related) BP levels.73–76 These 
observational findings may be because of reverse causality 
because having BP-lowering medication in old age probably 
reflects longer hypertension history with its consequences 
during life-course and, therefore, higher mortality risk than 
among people without medication. Another interpretation 
is that the medication-related decrease in BP in these very 
frail individuals could worsen – not improve – the progno-
sis. Although empirical support is lacking,53,60 we hypothesize 
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that, in the presence of severe frailty, altered circulatory auto-
regulation may cause tissue hypo-perfusion in instances of a 
significant drop in BP due to multiple antihypertensive drugs. 
Thus, in these individuals, an SBP <130 mm Hg in response 
to therapy might increase rather than decrease morbidity and 
mortality.77
High BP in older people is a complex and heterogeneous 
condition. When attempting to establish evidence-based on-
treatment BP targets, it becomes obvious that one size does 
not fit all.78 Therefore, strategies to verify the appropriateness 
and relevance of a given treatment over time during the course 
of changes in a patient’s status are welcome. For the time be-
ing, considering BP targets—thereby including individually 
adjusted upward when indicated—is probably the best means 
to avoid overtreatment not only at the initiation of therapy but 
also during follow-up.
Clinical Evaluation of Older Adults  
With Hypertension
In old subjects with suspected hypertension, a thorough his-
tory, physical examination, and a limited number of selected 
laboratory and complementary exams should be performed. 
The aim of these exams is 2-fold:
1. Answer the classical questions as for every subject with 
a new onset of hypertension, that is, confirm the pres-
ence of a permanent BP elevation, exclude a secondary 
hypertension and evaluate the global CVD risk.
2. Assess the global functional status of the subject (co-
morbidities, all medications, frailty, and autonomy).
Specificities of the Clinical Evaluation in Older 
Adults With Hypertension
Evaluation of patients >80 years usually differs from a 
standard medical evaluation. First and foremost, physicians 
must take into account that managing old patients is highly 
time-consuming because of several factors: complexity of the 
health condition because of multiple comorbidities, physi-
cal and cognitive slowness of older people, and the fact that 
most of the time, old frail subjects are accompanied by family 
members and professional caregivers with whom physicians 
have to discuss several issues.79 For very old patients, espe-
cially those who are frail, history-taking and physical exami-
nation might have to be done at different times, and physical 
examination might even require 2 sessions because patients 
become exhausted.80
The diagnosis of hypertension should be based on at least 
3 different BP measurements, taken on 2 separate office vis-
its. The rules of office BP measurements are the same as for 
younger individuals. One specific point is the necessity of 
having, in addition to regular size and overweight cuffs, child-
size cuffs for those older individuals with very low body mass 
index.
Generally, BP should be measured in sitting position. To 
assess orthostatic reaction, BP should be measured first in su-
pine followed by upright position. This is particularly impor-
tant to perform before any start of treatment and before any 
change in treatment. The measurements should be confirmed 
by home self-measurements to better assess BP levels and e-
liminate white coat reactions. Although informative, 24-hour 
ambulatory BP measurements are of limited interest in very 
old patients and not always very well tolerated.81 The main 
interest of these measurements is the detection of possible 
relationships between BP levels and symptoms, especially in 
treated hypertensive subjects
Secondary (potentially curable) hypertension needing 
a specific therapeutic intervention is not a very frequently 
encountered situation in older hypertensive patients. 
Therefore, it might be less useful for the older patient and 
less cost-effective to perform an extensive workup for the 
majority of older patients with hypertension.82,83 Symptoms 
associated with high BP, especially certain typical symp-
toms of secondary hypertension observed in younger hyper-
tensive subjects, are much less frequent and less specific 
in older individuals, primarily because of the presence of 
multiple comorbidities. However, when an older patient ex-
hibits an abrupt elevation of both SBP and DBP, a sudden 
deterioration of what was previously well-controlled hyper-
tension, resistant hypertension, or clinical and biological 
indications suggestive of a particular form of secondary hy-
pertension, then reversible causes should be suspected and 
investigated. The assessment and management of secondary 
hypertension are often more complicated in older patients. 
For example, although it is not uncommon to find evidence 
of atherosclerotic renal artery stenosis in older patients, it is 
often difficult to determine whether an identified atheroscle-
rotic lesion in the renal artery is an incidental finding or is 
responsible for the elevation in BP.
Currently, the therapeutic strategy for a renovascular hy-
pertension is to begin with a standard medical treatment as 
in essential hypertension and consider endoluminal or other 
interventions only after failure of the medical treatment.84 
Moreover, the indications for percutaneous or surgical inter-
ventions in case of renovascular hypertension should be ju-
diciously considered because these interventions may be less 
efficacious and riskier in frail older individuals.85 Sleep apnea 
is an often unrecognized but relatively common cause of high 
BP in older age. It should be considered in overweight indi-
viduals and those who complain of daytime somnolence or 
present snoring or irregular breathing during sleep.86 Chronic 
renal insufficiency, obstructive nephropathy, and thyroid di-
sease are other potential secondary causes of hypertension in 
older individuals. Assessment of serum creatinine alone may 
overestimate renal function in older patients. Alternatively, 
available formulas estimating the glomerular filtration rate 
should be used.87
Among other causes of secondary hypertension, medi-
cation-related BP elevation should always be investigated. 
Patients should specifically be questioned on use of nonste-
roid anti-inflammatory drugs, nasal decongestants, cortico-
steroids, hormone replacement therapy, ephedrine-containing 
supplements, and other over-the-counter preparations, which 
many patients do not view as medication and fail to mention 
their use unless specifically asked.
Finally, resistant hypertension may also be because of 
nonadherence (eg, because of cognitive decline), and possible 
causes should be appropriately investigated.
Determining global CVD risk is currently advocated 
by guidelines in addition to the standard procedures of BP 
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assessment. Global risk assessment should take into account 
certain specificities for older adults, including
 • Personal rather than family history is of importance. 
Indeed, with aging, heredity plays a less pronounced 
role, and it is more difficult for an older person to re-
member parents’ medical problems.
 • Auscultation and palpation investigating for a widened 
abdominal aortic pulsation and arterial bruits are use-
ful for the diagnosis of abdominal aortic aneurysm with 
possible interventions providing a significant clinical 
benefit. Suspicion must be verified with ultrasound.
 • BP change from supine to upright position should be sys-
tematically measured in older hypertensive subjects inde-
pendently of symptoms such as dizziness, falls, or syncope.
 • Assessment of arterial stiffness and intima-media thick-
ness may be of help to better identify older but still ro-
bust hypertensive subjects at high risk of CVD compli-
cations. Evidence from large clinical trials in the very 
old, however, still remains weak.88
Evaluating Frailty Level and Functional Status
As aforementioned, the term frailty is used to denote a mul-
tidimensional syndrome of reserve loss leading to a decline 
of physical, cognitive, psychological, and social functioning. 
Frailty is tightly related to, and even predictive of, the risk of de-
pendence, hospitalization, institutionalization, and death.6,9,89,90
During the past 10 to 15 years, various clinical studies 
have produced a vast amount of evidence indicating that as-
sessment of both frailty and functional status can provide val-
uable information in 3 fields,91–95 namely
 • Assess the risks of functional decline, morbidity, and 
mortality.
 • Propose specific actions to prevent or to slow frailty.
 • Define the risk/benefit balance of aggressive and chronic 
treatments and, therefore, adapt the therapeutic strate-
gies in older adults. This approach avoids using age—or 
traditional specialty-specific scores—as sole criteria in 
the provision of health and social care services.
In the context of treatment of high BP levels, this last aspect 
is of major importance and will be further developed in the 
next chapters.
Aside from, and partly because of the lack of consen-
sus in its definition, the detection of frailty encounters many 
challenges.
First, frailty is a multidimensional clinical entity, and its 
phenotypic presentation can be extremely heterogeneous in 
severity.
Second, frailty is a continuous phenomenon, and in real-
ity, all older subjects present some degree of frailty and func-
tional decline as compared to much younger individuals. It is, 
therefore, necessary to define the level of frailty, which can 
be considered as significant according to the objectives of the 
evaluation.
Third, assessment of frailty and functional status is 
time-consuming and often requires special skills. These fac-
tors, along with the fatalistic ageistic perception that not many 
things can be done to treat geriatric problems and to prevent 
their natural evolution, has led to the contention that the eval-
uation and management of frailty concerns only organized, 
multidisciplinary, specialized geriatric settings. This opens a 
vast field of potential public health frailty screening strategies 
to be implemented.
The multitude of scales for measuring frailty and their het-
erogeneity reflect these different aspects. Certain scales are al-
most exclusively aimed to detect the physical consequences of 
frailty,7,93–95 whereas others are much more multidomain91,92; 
some of these scales are very short and thus more adapted 
for rapid evaluation of frailty, whereas others are much more 
complete and obviously more time-consuming.
In the present review, we have chosen a visual and practical 
tool to determine functional profiling, which can guide treatment 
decisions. This visual score is based on the score established by 
the Canadian Study of Health and Ageing (CSHA).96
Evidence for the Benefits of Antihypertensive 
Treatment in Older People
Benefits on Cardiovascular Outcomes
HYVET showed in the setting of an RCT the beneficial ef-
fect of antihypertensive treatment versus placebo) on car-
diac mortality and several other cardiovascular outcomes in 
octogenarians.97 More recently, another RCT, the SPRINT 
(Systolic Blood Pressure Intervention Trial), showed ben-
efits for a lower BP goal of SBP <120 mm Hg in patients 
aged over 75 years,98 albeit after excluding patients with 
loss of autonomy, cognitive disorders, diabetes mellitus, 
and history of stroke. Based mainly on the HYVET trial, 
the 2013 European Society of Hypertension/European 
Society of Cardiology Guidelines99 for the management of 
arterial hypertension stated that in the elderly, there is evi-
dence for benefits of antihypertensive treatment when treat-
ing individuals with initial SBP of >160 mm Hg, whose 
SBP was reduced to values <150 mm Hg. Guidelines also 
recommend that if pharmacological treatment for high BP 
results in lower SBP (eg, <140 mm Hg) and treatment is not 
associated with adverse effects on health or quality of life, 
treatment does not need to be adjusted.
Interestingly, a post hoc analysis of both HYVET100 and 
SPRINT98 did not find a relationship between the benefits of anti-
hypertensive treatment and patient frailty. Therefore, both studies 
concluded that antihypertensive treatment strategies and goals in 
frail older patients should be similar to treatment strategies used 
in the fittest subgroups of patients, with these results being ulti-
mately incorporated in the 2017 Canadian guidelines.101,102
However, the very frail subjects were excluded from both 
the HYVET97 and SPRINT trials98 as was also the case in 
almost all previous clinical trials.12 Moreover, these 2 tri-
als were conducted in selected populations of relatively fit 
community-dwelling individuals and, furthermore, excluded 
those with clinically significant cognitive decline and demen-
tia, multiple cardiovascular and other comorbidities, ortho-
static hypotension, metabolic disorders, as well as patients 
with loss of autonomy.103 The exclusion criteria in these 2 
studies presented in Table 2 clearly indicate that the main 
findings cannot be automatically extrapolated to the totality 
of patients aged over 80 years. In addition, there is an open 
debate as to whether the method used for BP measurements 
in SPRINT potentially produces lower BP levels by 10 to 
15 mm Hg, which means that a BP level of 120 mm Hg in 
D
ow
nloaded from
 http://ahajournals.org by on July 22, 2019
Benetos et al  Hypertension Management in Older and Frail Older Patients  1051
SPRINT may correspond to a BP level of 130 to 135 mm Hg 
when using classical BP measurements.104,105
Benefits on Cognitive Function
An important dimension of benefit of antihypertensive treat-
ment would be the prevention of cognitive decline. Although 
epidemiological studies clearly indicate the relationship be-
tween higher BP and cognitive decline during long-term,53 
several methodological factors—such as short study dura-
tion, older participants—may explain the meager benefit for 
cognition in controlled studies (including HYVET) of BP 
lowering.59,60
These results seem to get some support, however, from 
a post hoc subgroup analysis of the recent Prevention of 
Dementia by Intensive Vascular Care trial; vascular care of 
70- to 78-year-old individuals in a health care setting for 6 to 
8 years affected neither primary nor secondary end points of 
cognitive function and autonomy.106 The authors explain the 
overall negative results by the lack of contrast in cardiovas-
cular risk reduction between the intervention and the control 
groups. They also suggest that the studied population was 
aged 70 to 78 years, whereas most observational data show an 
association between midlife hypertension and dementia.
Taken together, these results point out the importance of 
preventive and therapeutic actions to fight chronic high BP in 
younger ages. The BP goal to reach in order to obtain the best 
prevention of the cognitive decline and dementia remains 
unknown. Recently published results of the SPRINT MIND 
study (Systolic Blood Pressure Intervention Trial/Memory 
and Cognition in Decreased Hypertension)107 among adults 
with hypertension older than 50 years (average age 68 years) 
demonstrated that intensive BP control (SBP<120 mm Hg) 
compared with standard BP control (SBP<140 mm Hg) did 
not significantly reduce the risk of developing dementia. 
However, because of early study termination and fewer-than-
expected cases of dementia, the study might have been un-
derpowered for this end point. The current evidence from 
observational and interventional studies does not support a 
clear benefit on cognitive function when starting antihyper-
tensive treatment in older people and could even be deleteri-
ous in the very old frail people.
Decision-Making Process in the Initiation and 
Follow-Up of Antihypertensive Treatment
Many patients may be reluctant to adhere to a given treatment, 
even when its benefits are clearly supported by clinical tri-
als.108 There are few studies on patient drug adherence in old 
age, although it seems obvious that both initial patient accept-
ance and long-term adherence are management issues that do 
not get simpler with increasing age. Beyond initial acceptance 
and implementation, antihypertensive treatment implies fol-
low-up appointments, adjustments in drug schedules, and the 
burden of possible side effects. Patient adherence and even 
safety are better when these patients are involved in the deci-
sion-making process and are convinced of its benefits. Even 
when statistically significant, the benefits of a given treatment, 
in the patient’s view, may be insufficient to warrant the effort. 
Physicians themselves may not always be convinced that the 
benefits of treatment are clinically relevant. Evidence from 
RCTs is typically based on observations in selected popula-
tions corresponding more or less to the actual patients treated 
by physicians. Again, it is also worth noting that control pa-
tients are often treated better than patients at large, the result 
of which is apt to lessen the differences between control and 
intervention groups. In a clinical study in older patients un-
der antihypertensive treatment in Switzerland, only a small 
minority (4%–7%) clearly refused treatment.108 Most patients 
wanted extensive medical information, although preferred 
delegating the final medical decisions to their physician
Patients’ preferences—and reluctance—must be under-
stood and dealt with before taking a decision to treat or not 
to treat. Initial acceptance does not mean that patients under-
stand and accept long-term therapy. A shared decision-mak-
ing with regard to the treatment plan, which favors safety and 
adherence, requires detailed explanations not only at initiation 
but also repeatedly during follow-up. Shared decision-making 
is considered to be more complicated in the context of older 
age and multimorbidity. It is, however, highly relevant. Older 
patients with multimorbidity often face preference-sensitive 
decisions (ie, when ≥1 medically reasonable option is avail-
able and when there is no best strategy because the option 
depends on the patient’s personal values and preferences) with 
regard to starting, continuing, and stopping medications.
Table 2. Main Exclusion Criteria in HYVET and SPRINT Trials
Age, y SBP DBP
BP Regulation 
Physiopathology Main Risks Better BP Risk Marker Management
65–80 ↑ ↑ ↑ High PR and AS CV complications, c
ognitive decline
High SBP Physical activities, a
ssess TOD and global CVR, 
medical tt (SBP <140)
65–80 ↑ ↔ ↓ High AS CV complications, c
ognitive decline
High SBP, PP, 
low DBP
Physical activities, a
ssess TOD and Global CVR, m
edical tt (SBP <140)
>80 ↑ ↑ ↔ ↓ High AS CV complications, f
alls
High PP, low 
DBP, OH
CGA, medical tt
 (SBP <150 or SBP <140 
according functional status)
>80 ↔ ↓ ↔ High AS and c
omorbidities
CV complications, f
alls, loss of autonomy
Normal/low SBP, low DBP, 
normal/high PP, OH
CGA, deprescribing if SBP<130 
or OH, fight polypharmacy
AS indicates arterial stiffness; BP, blood pressure; CGA, Comprehensive Geriatric Assessment; CV, cardiovascular; CVR, cardiovascular risk; DBP, diastolic 
blood pressure; HYVET, Hypertension in the Very Elderly Trial; OH, orthostatic hypertension; PP, pulse pressure; PR, peripheral resistance; SBP, systolic blood 
pressure; SPRINT, Systolic Blood Pressure Intervention Trial; TOD, target organ damage; and tt, treatment.
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Guidelines for BP Goals and Therapeutic 
Strategies in Older Patients With High BP
Blood Pressure Goals
The 2013 European guidelines based on the HYVET criteria 
recommend initiating an antihypertensive strategy in individu-
als ≥80 years with an SBP >160 mm Hg, and targeting SBP to 
<150 mm Hg.99 The more recent North American Guidelines 
propose not to modify therapeutic targets based on age and 
frailty level.101,102 It is, however, very difficult to find common 
BP goals in the different National and International guidelines:
The Canadian 2017 guidelines propose to target an SBP of 
<120 mm Hg for all individuals aged over 75 years.101 The 2017 
American College of Cardiology/American Heart Association 
guidelines indicate that a BP <130/80 mm Hg should be tar-
geted after the age of 65 years.102 The 2018 guidelines propose 
a BP goal of <140/90 mm Hg for individuals older than 65 
years.109 Finally, the 2017 American College of Physicians/
American Association of Family Physicians guidelines pro-
pose to target a BP <150/90 mm Hg.110
One can also observe important discrepancies in the defi-
nition of elderly or older adults. In the clinical studies during 
the 80s on the Hypertension in the elderly subjects over 60 
or 65 years old were included, whereas presently this defi-
nition is mainly used for subjects >75 or >80 years old. This 
diversity is also found in the above-mentioned guidelines with 
variable age thresholds between 65 and 80 years old. We rec-
ognize that although these discrepancies are highly confusing, 
they reflect the dramatic demographic, cultural, and biomed-
ical changes of the last few decades and the vast heteroge-
neity in functionality among older subjects. For this reason, 
we think that functionality/frailty/autonomy criteria for the 
potential adaptation of therapeutic strategies. We use often the 
age threshold of 80 years to define older individuals because, 
currently, the percentage of people with severe loss of func-
tionality and loss of autonomy dramatically increases after 
that age. For this reason, the specific diagnostic and therapeu-
tic strategies discussed in this article mainly apply to individu-
als aged ≥80 years.
Therapeutic Strategies
With regard to nonpharmacological interventions for lower-
ing BP, although benefits have been shown in younger pop-
ulations, there is little evidence from controlled studies in 
hypertensive patients aged 80 plus. Some of the proposed 
lifestyle changes,111 including weight reduction, Dietary 
Approaches to Stop Hypertension/Mediterranean diet, die-
tary sodium reduction, physical activity, and moderate alcohol 
consumption may, however, not be appropriate or relevant and 
may even be detrimental. Thus, a weight reduction in patients 
>80 years easily induces a loss of muscle mass (sarcopenia) 
and can even cause cachexia, unless an intensive physical 
training program and adequate protein supplementation are 
concomitantly applied.112
Equally, an excessive salt reduction might induce hy-
ponatremia, malnutrition, and orthostatic hypotension with 
increased risk of falls. Physical activity adapted to the func-
tional capacities of the older person and to his or her prefer-
ences is of major importance, even if not meeting the amount 
recommended by current guidelines, which is similar for older 
and younger adult subjects.113 Finally, excessive alcohol in-
take should be discouraged, not only because of its pressor 
effect but also mainly because of increased risk of falls and 
confusion.
In older individuals, in which polypharmacy (including an-
tihypertensive agents) is a frequent phenomenon, drug-related 
problems are directly correlated with the number of drugs and, 
therefore, starting with monotherapy should be the rule.
Most international guidelines propose the same 5 anti-
hypertensive drug classes as for younger subjects: thiazide 
diuretics, calcium channel blockers, angiotensin-convert-
ing enzyme (ACE) inhibitor, angiotensin receptor blockers 
(ARB), and beta blockers (BB). The American guideline on 
antihypertensive treatment in patients >60 years lists the ad-
verse effects of drug classes but does not specifically advo-
cate a particular drug class.110 The British NICE guidelines 
(National Institute for Health Care Excellence) do not include 
BB as a first line treatment in older adults.114 The European 
guidelines mostly favor a calcium channel blocker or a thia-
zide diuretic in the absence of a compelling disease-specific 
indication, in addition to lifestyle change recommendations 
when the latter is insufficient to achieve BP control.99 We have 
furthermore recently proposed that in patients >80 years, ACE 
inhibitors should be among the first line medications because 
these represented 1 of the 2 drug classes used in HYVET.115 
However, the findings of some clinical studies argue against 
the use of ACE inhibitor as the first choice in older adults116 
and propose replacing them by ARBs.117
It is important to regularly check for all potential clinical 
and biological side effects and the impact of these treatments 
on the functional status and quality of life of the older patients. 
Table 3 shows the most frequent adverse effects of these drugs 
and the precautions to be considered in older adults. However, 
we should always bear in mind that in this population, med-
ication-induced side effects are more frequent, more severe, 
and less specific than in younger adults.118 Hence, all antihy-
pertensive drugs can be responsible for certain common clin-
ical manifestations and conditions such as fatigue, confusion/
delirium, orthostatic hypotension, and falls.
A combination antihypertensive therapy to control BP 
should be considered in the course of treatment only if the 
indication seems relevant after a judicious benefit/risk assess-
ment. According to authors’ experience, a third drug can be 
added if necessary, after a new medication review to avoid 
drug-related side effects. Moreover, great care must be taken 
if >3 antihypertensive drugs are combined in individuals aged 
over 80 years.
Should Frailty Status Influence 
Antihypertensive Treatment in Older Adults?
Several studies have demonstrated that stratification of older 
patients based on the level of frailty and functional status 
could greatly improve and predict short and long-term compli-
cations of therapeutic strategies when treating cardiovascular 
and metabolic diseases, such as diabetes mellitus,119 chronic 
heart failure,120 transcatheter aortic valve replacement,121 car-
diac surgery,122 and atrial fibrillation.123 In this respect, it is 
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equally important to take into account the frailty and func-
tional status when treating hypertensive patients.
The objective is to make the optimal choice of diagnos-
tic and therapeutic strategies to avoid an a priori exclusion 
because of advanced age and aggressive therapies targeting 
only life prolongation. This task is achieved by assessing the 
degree of frailty to define the benefit/risk ratio of diagnostic 
and therapeutic strategies of older patients with CVD. At pre-
sent and in the future, cardiologists are faced with managing 
an increasing number of older patients, with the mean age of 
Table 3. Antihypertensive Drugs: Adverse Effects and Precautions in Individuals Aged 80+ Years
Drug Class Most Common Adverse Effects Special Precautions/Considerations in Old Individuals
CCB
Dihydropyridine CCB
Non dihydropyridine CCB
Signs related to sympathetic activation 
(flushing, headache, tachycardia) are less 
frequent than in younger subjects.
Lower limb edema (frequent since many 
other factors for LLE).
Bradycardia, AV block, worsening heart 
failure, constipation (verapamil), fatigue, 
dyspnea.
LLE, which is relatively frequent with these drugs, can be erroneously interpreted as 
a clinical sign of heart failure. In addition, LLE can contribute to the decrease in social 
and physical activities for practical reasons (difficulties in walking with shoes).
Second-line selection; diltiazem can also cause LLE.
With verapamil, LLE is unusual, but constipation may be a major problem in very old 
individuals, as it can lead to fecal impaction, with nausea, anorexia, delirium, and 
functional decline.
Never combine verapamil with β-blockers.
Diuretics
Thiazide
Loop diuretic
Hyponatremia, hypokalemia, hyperuricemia 
and gout attacks, hypotension, dehydration.
Similar to Thiazides
For both thiazide and loop diuretics:
 Diuretic should be titrated according to the patient’s volemic status. The latter 
may be difficult to assess in very old and frail individuals. Creatinine and electrolyte 
monitoring is warranted after each dose change.
 Association with SSRI antidepressants increases the risk of severe hyponatremia.
  Risk of aggravation of urine incontinence. For this reason, diuretics may have 
an impact on the social life of the patient and can contribute to his/her isolation. 
Other patients often do not take their treatment if they want to have outdoor 
activities.
Thiazide-like indapamide has been tested in the only RCT specific for subjects 
>80 y.
Small doses (up to 25 mg of HCTZ or equivalent) are safe and well tolerated.
Loop diuretics are not indicated for hypertension unless there is severe renal 
insufficiency (estimated creatinine clearance <30 mL/[min·1.73 m2]). In the presence 
of both hypertension and heart failure, loop diuretics can be used for both diseases, 
either alone or in combination with thiazides.
ACE inhibitors Dry cough, hyperkalemia, rash, 
angioedema, dizziness, fatigue, acute renal 
failure
ACE inhibitors have been tested in the only RCT specific for subjects >80 y.
Avoid if you suspect dehydration, do not simultaneously increase diuretics to avoid a 
worsening in renal function.
Regular control of creatinine and potassium levels.
Angiotensin II receptor 
antagonists
Hyperkalemia, rash, dizziness, fatigue, 
acute renal failure
The same as for ACE inhibitors: Do not combine ARB with ACE inhibitor or renin 
inhibitor. Be cautious with aldosterone antagonist because of increased risk of 
hyperkalemia.
β- adrenoreceptor 
antagonists (β-blockers)
Bradycardia, cardiac decompensation, 
peripheral vasoconstriction, bronchospasm, 
fatigue, depression, dizziness, confusion, 
hypoglycemia
Fatigue, which is multifactorial in older subjects, can be accentuated. Nightmares, 
sleep disturbances, depression, and confusion may be present especially for the β-
blockers crossing the blood brain barrier.
Cardiac conduction problems can also be aggravated.
Caution when used in combination with acetylcholinesterase inhibitors (for Alzheimer 
disease): risk of major bradycardia.
Aldosterone antagonists Hyperkalemia, hyponatremia, and 
gastrointestinal disturbances, including 
cramps and diarrhea, gynecomastia
Aldosterone antagonist should not be given in instances of severe renal insufficiency, 
estimated creatinine clearance <30 mL/(min·1.73 m2) or hyperkalemia. Creatinine and 
electrolyte monitoring is warranted after each dose change.
α-adrenoreceptor 
antagonists (α-blockers)
Dizziness, fatigue, nausea, urinary 
incontinence, orthostatic hypotension, 
syncope
Usually not indicated.
Risk of hypotension (orthostatic, postprandial) and syncope.
Central α-
adrenoreceptor agonists
Drowsiness, dry mouth, dizziness, 
constipation, depression, anxiety, fatigue, 
urinary retention or incontinence, orthostatic 
hypotension, confusion, and delirium
High risk of delirium and confusion.
Depression, which is atypical and frequent in older subjects (and tricky to diagnose vs 
cognitive disorders), can be aggravated.
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blockers; AV, atrioventricular; CCB, calcium channel blockers; LLE, lower limb edema; 
HCTZ, hydrochlorothiazide; RCT, randomized controlled trial; and SSRI, selective serotonin reuptake inhibitors.
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patients hospitalized in cardiology departments currently of-
ten >80 years.124 The main consequence of these demographic 
changes is the presence of multiple comorbidities, geriatric 
syndromes, frailty, and loss of autonomy—all of which com-
plicate the evolution and treatment of chronic CVD.
Among older adults with heart failure, management is 
further hindered by other common geriatric impairments, 
including incontinence, falls, and frailty.125 In addition, the 
vast majority of hospitalized patients in geriatric depart-
ments present multiple chronic CVD risk factors and disease, 
such as hypertension, diabetes mellitus, atrial fibrillation, 
heart failure, valvular disease, ischemic heart disease, etc.126 
Consequently, geriatric cardiology (or cardio-geriatric medi-
cine) has been—and needs to be further—developed to com-
bine several decisional factors: age-attuned evidence-based 
management of CVD, comprehensive geriatric assessment 
(CGA), medication optimization, team-based coordination of 
care, and involvement of the patient and his/her caregivers in 
decision-making.127
Therefore, the best answer to the key question “should 
frailty level influence therapeutic strategies when treating hy-
pertensive older people?” is to define the threshold of frailty 
and functional decline beyond which treatment should be 
adapted. In our expert review published in 2016, we defined 
this threshold as “people living in nursing homes or needing 
assistance on a daily basis for their basic activities” which as 
mentioned may represent up to 35% of those aged over 80 
years.115 These are in fact the individuals who
 • Showed negative relationships between BP levels and 
morbidity-mortality, especially when receiving antihy-
pertensive medications.
 • Have always been excluded from clinical trials which 
have established the benefits of antihypertensive 
treatment.
Adequately defining the proper threshold helps to assess 
whether the expected benefits of treatment outweigh the 
risks in such a population with decreased life expectancy and 
decreased tolerance to stress.128 The CGA method, that is, a 
multidisciplinary diagnostic and treatment process in addi-
tion to assessment of multimorbidity,129,130 identifies medical, 
psychosocial, and functional limitations of an older person 
to develop a coordinated plan to maximize overall health 
with aging,131,132
However, in most cases, CGA is too complex and highly 
time-consuming for nongeriatricians. Thus, an effort should 
be made to propose valid algorithms for the classification of 
older patients according to their functional status, which is 
both fast and can be performed by most health profession-
als. Figure 1 is an example of classification according to the 
frailty status based on the CSHA score.96,133 This visual nu-
meric scale represents a practical decision-making tool to a-
dapt antihypertensive strategies. We propose this approach to 
discriminate between 3 profiles of patients, that is, those with 
preserved functional status (preserved function, groups 1–3 of 
the CSHA score), those with loss of function but preserved au-
tonomy for the ADL (loss of function/preserved ADL, groups 
4–5 of the CSHA score), and those with severe loss of func-
tional impairment and loss of autonomy for the ADL (loss of 
function and altered ADL, groups 6–9 of the CSHA score).
The therapeutic strategies for BP lowering in each of these 
3 groups are further expanded in the following section and 
schematically depicted in Figure 2.
Adaptation of the Treatment in 3 Different 
Functionality/Autonomy Groups
Older Adults With Preserved Functional Status 
(Preserved Function Profile)
This profile includes functionally independent older subjects 
without medically relevant comorbidity or those with satis-
factorily-controlled disease symptoms and without signifi-
cant impact on functional status. In these patients, we should 
consider full therapy to achieve outcomes similar to that of 
younger patients.
Older Adults With Moderate Functional Decline 
and Preserved Autonomy For ADL (Loss Of 
Function/Preserved ADL Profile)
Older subjects with this profile have moderate functional de-
cline and a dependence in instrumental ADL (IADL) in the 
absence of dependence in ADL. Patients of these groups com-
monly have 1 or 2 comorbidities, as well as moderate cogni-
tive and functional decline (consider adapted/tailored therapy 
including deprescribing).
We estimate that an important percentage of these patients 
(probably 25% to 40% for group 4 and the large majority of 
group 5) were excluded from the HYVET, hence the reason 
we consider subjects in these groups as being in a gray zone 
regarding evidence of treatment benefit.
To detect the presence and extent of frailty and impaired 
functional capacity in this profile, CGA should be performed. 
Indeed, CGA ultimately allows the identification of comor-
bidities, geriatric syndromes, and the degree of functional im-
pairment and loss of autonomy for the different ADL, thus 
allowing the possibility to consider tailored therapy: patients 
with few comorbidities and minor loss of autonomy will have 
antihypertensive therapeutic strategies similar to the preserved 
function profile, whereas those with multiple comorbidities, 
presence of geriatric syndromes, and dependence in ADL will 
have an approach similar to the loss of function and altered 
ADL profile described below.
Older Adults With Significant Loss of Function 
and Loss of Autonomy for ADL and Limited Life 
Expectancy (Loss of Function and Altered ADL)
This profile is identified by the presence of at least one of the 
following: multiple comorbidities, severe dementia, several 
geriatric syndromes, or dependence in ADL. Most patients in 
this group are aged ≥85 years.
Treatment in patients having this profile should be reas-
sessed, in addition to considering the possible use of a life ex-
pectancy calculator.134 Preserving symptom relief and quality 
of life is the primary goal of care. Drug prescription should 
very often be reevaluated for hierarchization of priorities and 
optimization. Because iatrogenic risk is very high, specialists 
should work closely with general practitioners (GPs), pharma-
cists, and caregivers.
Thus, while keeping SBP <150 mm Hg as the evi-
dence-based target, antihypertensive drugs should be reduced 
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or even stopped for safety reasons if SBP is lowered to SBP 
<130 mm Hg, or in cases of orthostatic hypotension, thus 
maintaining the 150 to 130 mm Hg on-treatment SBP values 
as a safety range.115 Other factors that may potentially be de-
creasing BP and inducing orthostatic hypotension, including 
malnutrition, dehydration, and other medications, should be 
identified and corrected.
A particular effort should be made in educating physicians 
on also deprescribing antihypertensive drugs when neces-
sary. There is also prospective, observational evidence that, 
among older individuals, deprescribing can save costs and 
be performed successfully without harm to the patient.135,136 
However, limitations of the existing evidence include, among 
others, (1) only few of the studies have investigated clini-
cal outcomes; (2) most of the trials had small sample sizes; 
(3) an insufficient duration of follow-up; and (4) insufficient 
power to detect clinically significant differences in outcomes. 
Specifically, there are no RCTs with antihypertensive drugs in 
this profile of patients. Such studies are desperately needed, 
given that physicians—especially GPs—are very skeptical 
and wary of reducing therapy in the CVD field. Again this 
situation points to the necessity for a close collaboration be-
tween GPs, geriatricians, cardiologists, pharmacists, and nurs-
es to modify prescribing/deprescribing practices. Naturally, 
close supervision of the patient after deprescribing is required.
Finally, we have previously pointed out the pressing ne-
cessity of solid scientific evidence based on registries, ob-
servational studies, large longitudinal cohorts, and mainly 
controlled trials in subjects with severe frailty.
Conclusions and Perspectives
There is an open debate on whether the management of arte-
rial hypertension, and more specifically the treatment goals 
of antihypertensive therapy, should be modified in octogenar-
ians according to their functional reserve and frailty levels. 
Chronological age should not be the main criterion for adapt-
ing therapeutic strategies, because of the large heterogeneity 
in the pace and consequences of the aging process among 
older adults. For this reason, geriatricians propose the assess-
ment of functional status and frailty through the CGA as a tool 
Figure 1. Profiles according to frailty and functional status in patients 80 years and over.96,133 This visual numeric scale based on the Canadian Study of 
Health and Ageing (CSHA) score represents a practical tool for the initial profiling of 80+ patients to help decide whether to adapt antihypertensive strategies. 
Subjects with a preserved function profile (groups 1–3 in the CSHA classification) feature a preserved functional status, are active and independent, possibly 
present chronic diseases, are well-controlled and their somatic and cognitive functionality remains satisfactory. On the other end of the spectrum, subjects 
with a loss of function and altered activities of daily living (ADL) profile (groups 6 to 9) require daily assistance for basic activities of daily living. In between, 
we identify subjects with a loss of function/preserved ADL’ profile (groups 4 and 5); these subjects are generally slowed down, have certain dependencies 
in instrumental ADL (IADL), although are generally autonomous for ADL. They may commonly have well-controlled comorbidities and moderate cognitive 
and functional decline. This profile requires a more detailed assessment of their functional status using the different scales for comprehensive geriatric 
assessment.
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to tailor the management of hypertension and other chronic 
diseases in older people.
Despite significant advances, CGA remains time-consum-
ing, complex, and difficult to apply in general clinical prac-
tice. This leads to indistinctness among health professionals 
regarding the understanding of who is frail and to what extent 
frailty should be taken into account when treating hyperten-
sion. This indistinctness has been facilitated by the lack of 
clinical trials in the more complex older patients with cog-
nitive and functional decline, multimorbidity, frailty, and 
disability.
 • In this review, we propose a pragmatic approach by clas-
sifying older patients in 3 functional profiles based on 
simple clinical criteria.
 • For individuals with preserved autonomy and preserved 
functionality (preserved function profile), strategies 
should be those proposed by the various national and in-
ternational guidelines for the younger old adults (65–75 
years).
 • For individuals with significant cognitive and functional 
decline, loss of autonomy, overt frailty, and limited life 
expectancy (loss of function and altered ADL profile), 
therapeutic strategies should be meticulously reas-
sessed and in which deprescribing is also considered as 
appropriate.
 • For individuals between these 2 groups, that is, those 
with moderate functional decline and frailty, but with 
preserved autonomy for ADL (loss of function/preserved 
ADL) profile, a more detailed geriatric assessment is 
needed to define the benefit/risk balance of the different 
therapeutic strategies.
These statements are predominantly based on observational data 
and on clinical experience, and, therefore, there is an imperative 
need for well-designed controlled clinical trials focused on the 
most frail older people to generate strong evidence relative to 
therapeutic strategies in this specific population group.
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